ASH Clinical News July 2017 V2 - Page 41

FEATURE evaluate alternative dosing regimens and predictive biomarkers. This resulted in the enrollment of more than 1,200 patients in the trial and, 3 years after the trial began, data from a cohort of 173 patients sup- ported the initial accelerated approval for the use of pembrolizumab in melanoma. Subsequent data from this trial have also supported accelerated approval for other indications and approval of a companion diagnostic test. This type of seamless development could provide earlier access to highly effe